Which beta blocker is least likely to contribute to weight gain?

Carvedilol is considered the beta blocker least likely to contribute to weight gain due to its unique pharmacological profile. Unlike other beta blockers, carvedilol is a non-selective beta blocker with additional alpha-blocking properties. This dual mechanism helps to counteract some of the adverse metabolic effects commonly associated with weight gain, such as fluid retention and alterations in lipid metabolism that can occur with other beta blockers.

Other options, such as atenolol, propranolol, and metoprolol, have been associated with varying degrees of weight gain. Research indicates that these drugs can influence body weight through different mechanisms, including effects on resting energy expenditure and appetite that lead to weight increase.

In contrast, carvedilol has shown a more neutral effect on weight, and some studies even suggest potential benefits in body weight management, especially in patients with heart failure and metabolic syndrome. This distinction makes carvedilol a preferable choice when considering a beta blocker for patients who are also managing weight concerns.